These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33851617)

  • 1. Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2).
    Amina B; Lynda AK; Sonia S; Adel B; Jelloul BH; Miloud M; Tewfik S
    Indian J Pathol Microbiol; 2021; 64(2):254-260. PubMed ID: 33851617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
    Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
    Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
    Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
    Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Mouron S; Manso L; Caleiras E; Rodriguez-Peralto JL; Rueda OM; Caldas C; Colomer R; Quintela-Fandino M; Bueno MJ
    Breast Cancer Res; 2021 Feb; 23(1):21. PubMed ID: 33579347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
    Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.
    Lim S; Koh MJ; Jeong HJ; Cho NH; Choi YD; Cho do Y; Lee HY; Rha SY
    Yonsei Med J; 2016 Jul; 57(4):831-9. PubMed ID: 27189274
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bofin AM; Ytterhus B; Klæstad E; Valla M
    J Clin Pathol; 2022 Jul; 75(7):459-464. PubMed ID: 33753561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
    Chen H; Singh RR; Lu X; Huo L; Yao H; Aldape K; Abraham R; Virani S; Mehrotra M; Mishra BM; Bousamra A; Albarracin C; Wu Y; Roy-Chowdhuri S; Kanagal-Shamanna R; Routbort MJ; Medeiros LJ; Patel KP; Broaddus R; Sahin A; Luthra R
    Oncotarget; 2017 Feb; 8(7):10845-10857. PubMed ID: 28125801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
    Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
    Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of
    Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
    World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
    Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
    Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
    [No Abstract]   [Full Text] [Related]  

  • 20. Calretinin expression as a reliable prognostic marker in different molecular subtypes of breast carcinoma.
    Farrag MS; El-Karef AA; Amin MM; Helal NM; Ali OF; Farrag NS
    Indian J Pathol Microbiol; 2017; 60(1):8-14. PubMed ID: 28195084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.